213 results match your criteria: "Cardinal Stefan Wyszyński Institute of Cardiology[Affiliation]"
Kardiol Pol
January 2025
Department of Nephrology and Internal Medicine, Medical Centre for Postgraduate Education, Warszawa, Poland.
Kardiol Pol
January 2025
Department of Congenital Heart Diseases, Cardinal Stefan Wyszyński National Institute of Cardiology, Warszawa, Poland.
Kardiol Pol
November 2024
1st Department of Arrhythmia, Cardinal Stefan Wyszyński National Institute of Cardiology, Warszawa, Poland.
ESC Heart Fail
November 2024
Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Background: Cardiac remodelling, a crucial aspect of heart failure, is commonly investigated in preclinical models by quantifying cardiomyocyte cross-sectional area (CSA) and microvascular density (MVD) via histological methods, such as immunohistochemistry. To achieve this, optimized protocols are needed, and the species specificity is dependent on the antibody used. Lectin histochemistry offers several advantages compared to antibody-based immunohistochemistry, including as cost-effectiveness and cross-species applicability.
View Article and Find Full Text PDFCardiooncology
September 2024
Department of Lymphoid Malignancies, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Advances in the diagnosis and treatment of adrenocortical carcinoma (ACC), along with the development of new therapeutic and diagnostic methods, have prompted a team of experts to formulate the first Polish guidelines for managing ACC. This article presents the diagnostic and therapeutic recommendations resulting from the discussion of specialists from various medical specialities, who participated in a series of online meetings aimed at developing consistent and effective recommendations under the National Oncology Strategy. These guidelines aim to optimise ACC treatment in Poland through coordinated efforts of multidisciplinary specialist teams, ensuring an effective and modern approach.
View Article and Find Full Text PDFKardiol Pol
July 2024
Department of Congenital Heart Diseases, Cardinal Stefan Wyszyński National Institute of Cardiology, Warsaw, Poland.
Curr Oncol Rep
October 2024
Department of Cancer & Cardio-Oncology Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena Str 5, 02-781, Warsaw, Poland.
Purpose Of Review: The goal of this paper is to summarize the data pertaining to the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) for the prevention of cardiotoxicity in patients receiving anthracyclines for cancer treatment. We discuss the potential efficacy of this class of medications, incorporating insights from existing literature and ongoing studies.
Recent Findings: SGLT2i are a class of medications which were initially developed for treatment of Type 2 diabetes and later extended to treat heart failure with reduced and preserved ejection fraction regardless of diabetes status.
J Comput Assist Tomogr
September 2024
From the Coronary and Structural Heart Disease Department, Cardinal Stefan Wyszynski Institute of Cardiology, Warsaw, Poland.
Objective: The aim of the study is to evaluate whether a pre-coronary artery bypass grafting (CABG) coronary computed tomography-based fractional flow reserve (FFR-CT) result at the site of a future anastomosis would predict the graft failure in patients undergoing CABG.
Methods: In 43 patients who had coronary computed tomography angiography (CCTA) prior to the CABG, follow-up CCTA were acquired >12 months post-CABG procedure. The FFR-CT values were simulated on the basis of the pre-CABG CCTA.
Kardiol Pol
May 2024
Unit for Screening Studies in Inherited Cardiovascular Diseases, Cardinal Stefan Wyszynski National Institute of Cardiology, Warszawa, Poland.
Background: In a population under 45 years of age, the predominant causes of sudden cardiac death (SCD) are inherited cardiac diseases. Determining the underlying cause may help identify relatives at risk and prevent further events but is more difficult if an autopsy has not been performed.
Aims: We aimed to assess the diagnostic value of clinical and genetic screening in relatives of young non-autopsied sudden unexplained death (SUD) victims.
Medicina (Kaunas)
February 2024
Faculty of Medicine, Jagiellonian University Medical College, 31-008 Kraków, Poland.
The assessment of coronary microcirculation may facilitate risk stratification and treatment adjustment. The aim of this study was to evaluate patients' clinical presentation and treatment following coronary microcirculation assessment, as well as factors associated with an abnormal coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) values. This retrospective analysis included 223 patients gathered from the national registry of invasive coronary microvascular testing collected between 2018 and 2023.
View Article and Find Full Text PDFFront Genet
February 2024
Department of Pediatric Cardiology and General Pediatrics, Medical University of Warsaw, Warsaw, Poland.
Hypertrophic cardiomyopathy (HCM) is a genetic condition with a prevalence of 1:500-1:3 000. Variants in genes encoding sarcomeric proteins are mainly responsible for the disease. gene encoding a myosin heavy chain beta, together with gene are the two most commonly affected genes.
View Article and Find Full Text PDFKardiol Pol
May 2024
Department of Cardiac Surgery and Transplantology, The Cardinal Stefan Wyszynski Institute of Cardiology, Warszawa, Poland.
Pol J Radiol
January 2024
The Cardinal Stefan Wyszyński National Institute of Cardiology, Warsaw, Poland.
The year 2023 marks 60 years since the first pacemaker was implanted in Poland. The number of implantable cardiac electrotherapy devices (CIEDs), including pacemakers, cardioverter-defibrillators, and resynchronization therapy systems, has been systematically increasing in the subsequent decades. It is estimated that nearly 500,000 Poles have an implanted cardiac electrotherapy device, making optimal diagnostic imaging with the use of magnetic resonance imaging (MRI) a clinically and epidemiologically important issue.
View Article and Find Full Text PDFKardiol Pol
February 2024
Department of Cardiology, University Clinical Hospital in Bialystok, Białystok, Poland.
Andexanet alfa (AA) is a recombinant inactive analog of human activated factor X (FXa), effectively reversing the effects of its inhibitors - rivaroxaban and apixaban, which are available in Poland. The drug was approved for clinical use registration after the publication of the results of the ANNEXA-4 trial (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXa Inhibitors 4), in which its efficacy in restoring hemostasis in life-threatening hemorrhages in patients receiving using the aforementioned anticoagulants was demonstrated. Hence, AA is now recommended for patients on apixaban or rivaroxaban therapy with massive and uncontrollable hemorrhages, including hemorrhagic strokes (HS) and gastrointestinal bleeding.
View Article and Find Full Text PDFKardiol Pol
March 2024
Department of Cardiomyopathy, National Institute of Cardiology, Warszawa, Poland.
Int J Mol Sci
December 2023
Institute of Physiology, Justus Liebig University, 35392 Giessen, Germany.
Arch Cardiovasc Dis
December 2023
Deutsches Herzzentrum München des Freistaates Bayern, 80636 München, Germany.
Background: The Amplatzer™ Trevisio™ Intravascular Delivery System (Trevisio DS; Abbott Laboratories, Chicago, IL, USA) facilitates the delivery of Amplatzer™ Occluders and features an ultraflexible tip, which improves assessment of occluder position before release.
Aims: To assess the safety and efficacy of the Trevisio DS for transcatheter closure of patent foramen ovale and atrial septal defect.
Methods: The Amplatzer™ Trevisio™ Intravascular Delivery System Post-Approval Study was a prospective, postmarket, single-arm, multicentre, observational study of the Trevisio DS.
Pol Arch Intern Med
December 2023
Department of Adult Congenital Heart Disease, The Cardinal Stefan Wyszynski National Institute of Cardiology, Warsaw, Poland
Pharmacol Rep
December 2023
Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, The Cardinal Stefan Wyszynski National Institute of Cardiology, Warsaw, Poland.
Background: Depressive disorder is a common comorbidity of chronic obstructive pulmonary disease (COPD); according to some studies, it occurs in approximately 80% of patients. The presence of depressive symptoms influences the quality of life and affects the course and treatment of this disease. The cause of depressive symptoms in COPD and the linking mechanism between COPD and depressive disorder have not been clearly elucidated, and more studies are warranted.
View Article and Find Full Text PDFSports Med
January 2024
Department of Epidemiology, Cardiovascular Disease Prevention, and Health Promotion, The Cardinal Stefan Wyszynski National Institute of Cardiology, Warsaw, Poland.
There are countless types of portable heart rate monitoring medical devices used variously by leisure-time exercisers, professional athletes, and chronically ill patients. Almost all the currently used heart rate monitors are capable of detecting arrhythmias, but this feature is not widely known or used among their millions of consumers. The aims of this paper were as follows: (1) to analyze the currently available sports heart rate monitors and assess their advantages and disadvantage in terms of heart rate and rhythm monitoring in endurance athletes; (2) to discuss what types of currently available commercial heart rate monitors are most convenient/adjustable to the needs of different consumers (including occasionally physically active adults and cardiac patients), bearing in mind the potential health risks, especially heart rhythm disturbances connected with endurance training; (3) to suggest a set of "optimal" design features for next-generation smart wearable devices based on the consensus opinion of an expert panel of athletes, coaches, and sports medicine doctors.
View Article and Find Full Text PDFEur Heart J
January 2024
Royal Brompton Hospital, Sydney Street, London, Greater London SW3 6NP, UK.
Background And Aims: Transcatheter pulmonary valve implantation (TPVI) is indicated to treat right-ventricular outflow tract (RVOT) dysfunction related to congenital heart disease (CHD). Outcomes of TPVI with the SAPIEN 3 valve that are insufficiently documented were investigated in the EUROPULMS3 registry of SAPIEN 3-TPVI.
Methods: Patient-related, procedural, and follow-up outcome data were retrospectively assessed in this observational cohort from 35 centres in 15 countries.
Kardiol Pol
December 2023
Unit for Screening Studies in Inherited Cardiovascular Diseases, Cardinal Stefan Wyszyński National Institute of Cardiology, Warszawa, Poland.
Kardiol Pol
November 2023
Chair and Department of Health Prophylaxis, Medical University of Poznan, Poznań, Poland.
Respiratory diseases have been the fourth most common cause of death in Poland in recent years. Respiratory infection, especially pneumonia, can lead to exacerbation of chronic cardiovascular disease.Streptococcus pneumoniae is the most common bacterial pathogen causing community-acquired pneumonia.
View Article and Find Full Text PDFCirc Genom Precis Med
October 2023
Institute of Cardiovascular Science, University College London, United Kingdom (D.E.C., A.P., A.B., P.S., M.L., P.M.E.).
Background: Variants in are reported in 2% to 6% of familial cases of dilated cardiomyopathy and may be associated with fatal ventricular arrhythmia and rapid heart failure progression. We sought to determine the risk of adverse events in variant carriers and the impact of sex on outcomes.
Methods: Consecutive probands and relatives carrying variants were retrospectively recruited from 12 cardiomyopathy units.